Avidity Biosciences - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
HomeAvidity Biosciences
Avidity Biosciences logo

Avidity Biosciences

0 followers

RNA

Performance

About Avidity Biosciences

Avidity Biosciences is a biotechnology company focused on developing a new class of targeted RNA therapeutics using its Antibody Oligonucleotide Conjugates (AOC™) platform. Starting with a muscle disease franchise, the company aims to address root causes of disease and expand its pipeline to additional tissues and therapeutic areas. Headquartered in San Diego, California, the organization emphasizes delivering RNA-based therapies to previously inaccessible cells and tissues. Their programs target diseases such as myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy, advancing toward broad patient impact.

Recent News

Recent Deals

Key Team Members

Sarah Boyce

President & CEO

Steve Hughes

Chief Medical Officer

W. Michael Flanagan

Chief Scientific Officer

Michael MacLean

Chief Financial Officer

Key Facts

HQ Location

San Diego, United States

Founded

2012

Employees

201 - 500

Status

Public

Website

https://aviditybiosciences.com